EMERGENCY:Status dystonicus — prolonged severe dystonic crisis —call040-46324365immediately — 24 hours, 7 days— 24/7
NBIA: When Iron Builds Up in Your Child's Brain — Understanding a Rare but Diagnosable Group of Conditions
NBIA is a group of rare inherited brain conditions in which iron builds up in the brain's movement centres, causing progressive dystonia and neurological decline. Expert NBIA diagnosis, genetic testing, and Deep Brain Stimulation (DBS) treatment at KIMS Neuroscience, Hyderabad.
Neurodegeneration with Brain Iron Accumulation
15 identified to date
Rare Inherited Neurodegeneration · Iron Metabolism Disorders
PKAN · PLAN · BPAN · MPAN
Paediatric Neurology · Movement Disorders · Neurosurgery · Genetics
Dystonia medications · Baclofen pump · Botulinum toxin · Deep Brain Stimulation · Genetic counselling
NBIA is a group of rare, inherited neurological conditions unified by one feature: abnormal iron accumulates in the basal ganglia and related brain structures, progressively damaging the neurons responsible for movement control. 15 distinct genetic subtypes have been identified. Most present in childhood or adolescence with progressive dystonia, rigidity, and neurological decline. The four most common subtypes are PKAN, PLAN, BPAN, and MPAN. NBIA is extremely rare (1–9 per million). At KIMS Neuroscience Hyderabad, we offer the most comprehensive NBIA service in South India — including genetic panel testing, MRI interpretation, and Deep Brain Stimulation for severe dystonia.
- What it is
- Group of 15 rare inherited conditions. Iron builds up abnormally in the basal ganglia, causing progressive dystonia and neurological decline. Most begin in childhood.
- Most common subtype in South India
- PLAN (PLA2G6-associated neurodegeneration) — not PKAN as in Western populations. This finding makes broad genetic panel testing essential for Indian patients, not subtype-specific testing only.
- Diagnosis at KIMS
- Brain MRI (each subtype has a characteristic iron pattern) · Full genetic panel (all 15 NBIA genes) · Ophthalmological assessment · Wilson's disease excluded first (mandatory).
- Wilson's disease exclusion
- Always done before NBIA is confirmed. Wilson's disease (copper accumulation, not iron) is treatable and must be excluded. Simple blood and urine test plus eye examination at KIMS.
- Treatment at KIMS
- Dystonia medications (trihexyphenidyl, baclofen, benzodiazepines) · Botulinum toxin · Intrathecal baclofen pump · Deep Brain Stimulation (GPi target) for severe dystonia.
- Emergency
- Status dystonicus: prolonged severe whole-body dystonic crisis with fever — call 040-46324365 immediately. Life-threatening without urgent management.
- Contact KIMS
- 040-44885000 · Paediatric neurology + movement disorders + neurosurgery (DBS) · Genetics on site
| Fact | Details |
|---|---|
| What it is | Group of 15 inherited disorders · abnormal brain iron accumulation in the basal ganglia |
| Four most common subtypes | PKAN · PLAN · BPAN · MPAN |
| South India insight | PLAN is more common than PKAN here — broad genetic panel is the correct first test |
| Diagnosis at KIMS | Brain MRI (subtype iron pattern) · full 15-gene panel · ophthalmology · Wilson's disease excluded first |
| Treatment | Trihexyphenidyl · Baclofen · Botulinum toxin · Intrathecal baclofen pump · DBS (GPi) for severe dystonia |
| Emergency | Status dystonicus — prolonged dystonic crisis with fever · 040-46324365 immediately |
| Contact | 040-44885000 · Paediatric neurology + movement disorders + neurosurgery · Genetics on site |
About This Condition
What Is NBIA?
If your child has been having increasing movement problems particularly involuntary twisting of the limbs (dystonia), stiffness, difficulty walking, or changes in speech and a brain MRI has shown unusual dark signals in specific areas deep inside the brain, you may be facing a diagnosis of Neurodegeneration with Brain Iron Accumulation, or NBIA.
NBIA is not a single disease. It is a group of rare, inherited neurological conditions that share one defining feature: abnormal iron accumulates in specific parts of the brain particularly the basal ganglia, a cluster of structures deep in the brain that coordinate movement damaging brain cells over time and causing progressive movement disorders, and in some types, cognitive and psychiatric changes.
What unites all NBIA conditions is that iron, which the brain normally contains in small controlled amounts, becomes excessive and toxic in specific brain regions. This excess iron gradually destroys the neurons in those regions. Exactly how this happens and which brain cells are affected differs between the various NBIA subtypes, which is why different forms of NBIA can look quite different clinically.
As of now, 15 distinct genetic disease entities have been identified under the NBIA umbrella, with the four most common forms being PKAN, PLAN, BPAN, and MPAN.
NBIA is extremely rare affecting approximately 1–9 people per million worldwide. Most types begin in childhood or early adolescence, though some present in adulthood. Most are inherited in an autosomal recessive pattern meaning both parents are carriers but unaffected themselves. One subtype, BPAN, is X-linked.
In India, a study from a Southern India tertiary care centre found that PLAN (PLA2G6-associated neurodegeneration) was the most common NBIA subtype in their cohort, followed by PKAN, a finding that may differ from Western populations and underlines the importance of broad genetic panel testing when NBIA is suspected in Indian patients.
At KIMS Neuroscience, Hyderabad, we offer comprehensive NBIA assessment including high-quality MRI interpretation, genetic panel testing, neurological and ophthalmological evaluation, multidisciplinary management, and Deep Brain Stimulation surgery for patients with severe, disabling dystonia.
Book a Consultation
Speak directly with our specialist team. No referral required. Monday to Saturday.
040-44885000International enquiries: info@kimsneurosciences.comWhat Are the Main NBIA Subtypes?
Each NBIA subtype has a different genetic cause, a different age of onset, and a somewhat different clinical picture. The following covers the four most common forms and the key less common ones.
PKAN — Pantothenate Kinase-Associated Neurodegeneration
PKAN is caused by mutations in the PANK2 gene. It is the best-characterised NBIA subtype and has a hallmark MRI finding — the "eye of the tiger" sign — that makes it one of the more readily diagnosable subtypes.
Classic PKAN begins before age 6, causes progressive dystonia, rigidity, and dysarthria, and typically leads to loss of independent walking within 10–15 years.
Atypical PKAN begins in the teens, progresses more slowly, and prominently features speech difficulties and psychiatric symptoms.
Full detailed information: → See our PKAN page
PLAN — PLA2G6-Associated Neurodegeneration
PLAN is caused by mutations in the PLA2G6 gene. It encompasses two distinct clinical presentations that were previously considered separate conditions:
Infantile Neuroaxonal Dystrophy (INAD): The more severe form, beginning in infancy (typically before age 3) with progressive motor and cognitive regression, hypotonia (low muscle tone), and visual deterioration. Iron accumulation may not be visible on MRI early in the disease, which can delay the diagnosis.
Atypical NAD / adult-onset PLAN: A later-onset form featuring dystonia, Parkinsonism, cerebellar ataxia, and prominent psychiatric symptoms (particularly psychosis and behavioural changes) appearing in late childhood to early adulthood.
In the Southern India cohort, PLAN was the most commonly identified NBIA subtype — making awareness of this condition particularly important for neurologists in South India. Inherited in an autosomal recessive pattern.
BPAN — Beta-Propeller Protein-Associated Neurodegeneration
BPAN is caused by mutations in the WDR45 gene, located on the X chromosome. It is unusual among NBIA conditions because it is X-linked dominant — typically affecting girls more severely, while boys with the mutation often die in early childhood or have very severe disease.
The clinical picture of BPAN is distinctive:
Childhood phase: Intellectual disability, seizures (often beginning in infancy), limited speech development, and autistic features. Iron accumulation on MRI may be absent or subtle in childhood.
Adult transition: In early to mid-adulthood, a sudden and dramatic deterioration occurs — Parkinsonism, dystonia, and dementia developing rapidly over months. This adult deterioration is often the point at which the NBIA diagnosis is first considered.
BPAN should be suspected in any girl with intellectual disability, early-onset seizures, and limited speech who reaches early adulthood and then deteriorates rapidly with movement and cognitive problems.
MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration
MPAN is caused by mutations in the C19orf12 gene. It typically begins in childhood or early adulthood, causing progressive gait difficulty, spasticity, dystonia, dysarthria, and optic atrophy. Psychiatric symptoms — particularly depression, obsessive-compulsive features, and psychosis — are common and sometimes precede the movement problems. Cognitive decline follows in later stages. Inherited in an autosomal recessive pattern.
FAHN — Fatty Acid Hydroxylase-Associated Neurodegeneration
FAHN is caused by mutations in the FA2H gene. It presents in childhood with leg dystonia, weakness, and falls alongside cerebellar ataxia (balance and coordination difficulties), optic atrophy, and white matter changes in the brain on MRI. Brain iron accumulation is typically seen in the basal ganglia. Inherited in an autosomal recessive pattern.
Neuroferritinopathy
Unusual among NBIA conditions because it is autosomal dominant — meaning only one copy of the mutated FTL (ferritin light chain) gene is needed to cause the disease. It is also unusual in presenting in adulthood rather than childhood, typically in the 40s or 50s. It causes progressive chorea, dystonia, and cognitive decline. The MRI shows characteristic iron accumulation in the basal ganglia and, uniquely, in the dentate nuclei of the cerebellum.
Aceruloplasminemia
Another adult-onset NBIA form, caused by mutations in the CP gene (ceruloplasmin). Iron accumulates not just in the brain but also in the liver and pancreas, causing the distinctive triad of: retinal degeneration, diabetes mellitus, and neurological disease (dystonia, cerebellar ataxia, dementia). The adult-onset and systemic features distinguish it from the childhood NBIA forms.
Kufor-Rakeb Syndrome (KRS)
Caused by mutations in the ATP13A2 gene, KRS causes juvenile-onset Parkinsonism alongside pyramidal signs, supranuclear gaze palsy, and in some patients, cognitive decline. It is sometimes described as a form of juvenile Parkinson's disease with additional features. KRS has been identified in India, and should be considered in teenagers presenting with juvenile Parkinsonism.
Idiopathic NBIA
In some patients, MRI shows the characteristic iron accumulation pattern in the basal ganglia and the clinical picture is consistent with NBIA, but genetic testing does not identify a mutation in any of the known NBIA genes. These patients are described as having idiopathic NBIA. As genetic testing technology improves and new NBIA genes are identified, some of these patients will receive a specific genetic diagnosis in the future.
What Causes NBIA?
Despite the different genes involved in different NBIA subtypes, they share a common downstream consequence abnormal iron handling and accumulation in specific brain regions, particularly the globus pallidus and substantia nigra.
Iron is essential for normal brain function it is involved in energy production, neurotransmitter synthesis, and myelin formation. The brain normally regulates iron levels carefully through a complex system of transport and storage proteins. In NBIA conditions, different genetic mutations disrupt different parts of this system affecting coenzyme A metabolism, phospholipid metabolism, mitochondrial function, or iron transport proteins directly but all ultimately result in excessive, toxic iron deposition in the movement-control centres of the brain.
Why iron accumulation damages specific neurons and why the basal ganglia are the most vulnerable region is an active area of research. The iron generates reactive oxygen species (chemically unstable molecules that damage cells), and over time this oxidative damage causes progressive neuronal death.
Inheritance Patterns Across NBIA Subtypes
Most NBIA conditions are autosomal recessive both parents carry one mutated copy of the relevant gene without being affected. Each pregnancy carries a 25% risk of an affected child.
BPAN is X-linked dominant caused by a mutation in the WDR45 gene on the X chromosome, typically arising as a new (de novo) mutation rather than being inherited from a carrier parent. Most cases of BPAN are sporadic new mutations.
Neuroferritinopathy is autosomal dominant one copy of the mutated FTL gene causes the disease, and each child of an affected parent has a 50% chance of inheriting it.
Genetic counselling covering the specific inheritance pattern of the confirmed NBIA subtype is provided as part of every NBIA diagnosis at KIMS Neuroscience, Hyderabad.
Diagnosis at KIMS
How Is NBIA Diagnosed at KIMS?
The diagnostic pathway for NBIA combines clinical assessment, brain MRI, ophthalmological evaluation, and genetic testing. The process typically begins with the MRI.
Step 1: Brain MRI — the critical first step
In most NBIA conditions, a T2-weighted brain MRI shows characteristic hypointense (dark) signal changes in the globus pallidus and substantia nigra reflecting the abnormal iron deposits in these regions. Each NBIA subtype produces a characteristic MRI pattern: • PKAN — the "eye of the tiger" sign: dark ring with a bright centre in the globus pallidus • PLAN (infantile form) — cerebellar and cerebral atrophy, with iron changes appearing later; T2 hyperintensity of cerebellar cortex early • BPAN — a distinctive "halo" pattern with T1 hyperintensity and T2 hypointensity in the substantia nigra and globus pallidus in the adult phase • MPAN — iron in the globus pallidus and substantia nigra with white matter changes and cerebellar atrophy • Neuroferritinopathy — iron in the basal ganglia and uniquely also in the cerebellar dentate nuclei; cavitation (cyst-like changes) within the basal ganglia in later disease • Interpreting these MRI patterns accurately requires a neurologist experienced in NBIA — the findings are specific but subtle, and a radiology report may not distinguish between subtypes or recognise early iron changes. At KIMS Neuroscience, our team reviews MRI images specifically for NBIA-related findings and can advise on the most likely subtype before genetic testing confirms the diagnosis.
Step 2: Genetic testing — confirming the subtype
Once NBIA is suspected on clinical and MRI grounds, a genetic panel test covering all known NBIA genes is the most efficient path to a confirmed diagnosis. This is a blood test the DNA from a blood sample is analysed for mutations in PANK2, PLA2G6, WDR45, C19orf12, FA2H, FTL, CP, ATP13A2, and other NBIA-related genes simultaneously. Confirming the specific gene mutation has several important consequences: • It confirms the exact NBIA subtype, which guides prognosis and management • It enables precise genetic counselling for the family • It allows targeted testing of siblings and family members • It opens options for prenatal or preimplantation genetic testing in future pregnancies
Step 3: Ophthalmological assessment
Several NBIA conditions cause retinal or optic nerve degeneration, a finding that both supports the diagnosis and needs to be documented for monitoring and support planning. Every NBIA patient at KIMS receives a formal ophthalmological assessment including fundoscopy and electroretinography at diagnosis.
Step 4: Neurological and neuropsychological assessment
A full neurological examination documents the pattern and severity of movement abnormalities particularly dystonia, which is rated using standardised scales (Burke-Fahn-Marsden) to enable meaningful tracking over time. Cognitive and neuropsychological assessment establishes baseline function and identifies any cognitive or psychiatric symptoms requiring management.
Step 5: Excluding Wilson's disease
This is mandatory before any NBIA diagnosis is confirmed. Wilson's disease copper accumulation in the brain is treatable, and it can produce basal ganglia signal changes on MRI that may initially suggest NBIA. A blood test for ceruloplasmin and a 24-hour urine copper, along with a slit-lamp eye examination for Kayser-Fleischer rings, is performed in every suspected NBIA case at KIMS. If Wilson's disease is found, treatment changes everything.
Treatment
How Is NBIA Treated at KIMS?
As of now, there are no curative treatments for any NBIA disorders. Management is focused on controlling the movement symptoms particularly dystonia and spasticity preventing complications, and supporting the child and family comprehensively through every stage. The treatment approach at KIMS mirrors that described in detail on our PKAN page, since dystonia management principles apply across NBIA subtypes. Key elements include:
Dystonia management — the central treatment priority
As of now, there are no curative treatments for any NBIA disorders. Management is focused on controlling the movement symptoms particularly dystonia and spasticity preventing complications, and supporting the child and family comprehensively through every stage. The treatment approach at KIMS mirrors that described in detail on our PKAN page, since dystonia management principles apply across NBIA subtypes. Dystonia in NBIA is the most disabling and often the most painful symptom. A stepwise approach is used at KIMS: Oral medications: Trihexyphenidyl (anticholinergic), baclofen, benzodiazepines, and tetrabenazine are the most commonly used agents. Multiple medications are typically tried often in combination before the best regimen for an individual patient is established. Dose escalation is gradual and carefully monitored.
Botulinum toxin injections
For focal or regionally limited dystonia particularly of the arms, neck, or oromandibular region — targeted botulinum toxin injections provide meaningful, temporary relief repeated every 3–4 months.
Intrathecal baclofen pump
For generalised spasticity and dystonia not adequately controlled with oral medications, an intrathecal baclofen pump delivers baclofen directly into the spinal fluid — far more effective at controlling generalised tone with fewer systemic side effects.
Deep Brain Stimulation (DBS)
For patients with severe, generalised, disabling dystonia that has not responded adequately to other treatments and where the overall condition and cognitive function allow the surgical and rehabilitation process DBS of the globus pallidus is the most powerful intervention available. The KIMS Neuroscience team Neuroscience, Hyderabad performs DBS for NBIA-related dystonia, with a comprehensive multidisciplinary pre-surgical assessment for every candidate.
Managing other symptoms by subtype
Seizures particularly prominent in BPAN are managed with standard anti-epileptic medications. Psychiatric symptoms depression, psychosis, OCD are managed with appropriate psychiatric medications, assessed and managed by our neuropsychiatry team. Parkinsonism in subtypes where Parkinsonism is prominent (KRS, adult PLAN, BPAN adult phase), a cautious trial of levodopa is reasonable, though response is variable. Visual deterioration monitored by ophthalmology with support planning for any adaptive equipment needed. Cognitive and intellectual disability supported by our neuropsychology team with formal assessments and recommendations for educational accommodations.
Research and emerging treatments
Deferiprone, an iron-chelating medication that removes excess iron from the body has been studied in PKAN and other NBIA conditions in clinical trials. Results have been mixed: the drug successfully reduces brain iron visible on MRI in some patients, but has not shown consistent clinical benefit in most studies. A discrepancy between radiological improvement and the absence of clinical benefit is observed in many cases perhaps because neuronal damage was already too advanced by the time treatment started, or because iron accumulation may be a secondary consequence rather than the primary driver of cell damage. Deferiprone is not currently a standard treatment for NBIA at KIMS, but our team monitors the research and will offer it when evidence supports it. Several gene therapy and small molecule approaches are in early clinical trial phases for specific NBIA subtypes. Our team stays current with international trial activity and will advise families on any trial opportunities that become available.
When Should You Seek Specialist Assessment for NBIA?
Come to KIMS Neuroscience, Hyderabad if:
Emergency: If a child with NBIA develops a prolonged, severe, generalised dystonic episode with fever or extreme distress this is status dystonicus, a medical emergency. Call 040-46324365 immediately.
A child has been having progressive difficulty walking, involuntary muscle twisting, stiffness, or speech deterioration
A brain MRI has shown dark signal changes in the basal ganglia or the substantia nigra
A child has unexplained developmental regression loss of motor or cognitive milestones previously achieved
A teenager or young adult has been diagnosed with juvenile Parkinsonism or unexplained dystonia
A child has intellectual disability, early-onset seizures, and limited speech, and is now developing movement problems in adolescence or early adulthood raising the possibility of BPAN
An adult has developed unexplained chorea, dystonia, or cognitive decline alongside diabetes and retinal problems raising the possibility of aceruloplasminemia or neuroferritinopathy
A sibling of a confirmed NBIA patient is showing any movement, developmental, or cognitive changes
What to Expect — Living with NBIA
The prognosis in NBIA varies considerably between subtypes and between individuals within each subtype. Early-onset, rapidly progressive forms such as classic PKAN and infantile PLAN follow a faster course, with significant disability developing within years of symptom onset. Later-onset, more slowly progressive forms such as atypical PKAN, MPAN, and the adult NBIA conditions may allow meaningful function for decades.
Across all NBIA conditions, the overriding principle of care at KIMS is this: every intervention that reduces pain, extends function, prevents dangerous complications, and supports the family is worth pursuing. Dystonia control, falls prevention, swallowing management, vision support, psychiatric care, and family genetic counselling are not peripheral they are the substance of good NBIA care.
For families in Hyderabad and across Southern India, KIMS Neuroscience provides the most comprehensive NBIA service available in the region including the diagnostic expertise, the genetic counselling infrastructure, and the surgical capability (DBS) that together represent the current best of what medicine can offer these patients.
Related Conditions
NBIA belongs to a broader family of neurodegenerative and movement-related disorders:
FAQs
Frequently Asked Questions
Has your child been diagnosed with NBIA, or has their brain MRI shown iron deposits in the basal ganglia?
KIMS Neuroscience, Secunderabad, Hyderabad offers the most comprehensive NBIA service in Southern India including specialist MRI interpretation, genetic panel testing, neurological and ophthalmological evaluation, multidisciplinary medical management, genetic counselling, and Deep Brain Stimulation surgery for patients with severe dystonia. You do not need to travel outside Telangana for specialist NBIA care.
info@kimsneurosciences.com